|
|
|
|
|
Stealth Pharmas
|
|
|
| By
Bill Trombetta
|
|
|
|
Second annual Not Big Pharma audit gives equal time to the little guys. Who's got the Midas touch?
|
|
|
|
Blueprint for Excellence
|
|
|
| By
John Moran
,
Chris Nickum
|
|
|
|
In a time of slow growth, true innovators forge new relationships with core customers
|
|
|
|
Being Bob: Q&A with Robert Essner
|
|
|
| By
Patrick Clinton
|
|
|
|
An industry legend weighs in on leadership, research, and sales models. Q&A with outgoing Wyeth Chairman Bob Essner
|
|
|
|
45 Under 45:The Change Generation
|
|
|
| By
Walter Armstrong
,
Joanna Breitstein
|
|
|
|
In our first ever Emerging Leadership Awards, we profile 45 talented young professionals who will lead pharma into the next generation
|
|
|
|
|
|
|
|
|
Mightier Than the Sword
|
|
|
| By
David Kweskin
,
Wes Michael
|
|
|
|
When it comes to marketing, every syllable speaks volumes
|
|
|
|
Doctor's Orders
|
|
|
| By
Sara Donnelly, Associate Editor
|
|
|
|
Dr. Michael Kessler and Mark Vitello of MD Mindset have the cure for the common sales pitch? Look at the transaction from the customer's perspective
|
|
|
|
The Web Video (R)evolution
|
|
|
| By
Matt DeLoca
|
|
|
|
Pharma is taking note of online video's power to affect B2B communications
|
|
|
|
|
|
|
|
|
Candidates Target Pharma
|
|
|
| By
Jill Wechsler
|
|
|
|
US presidential hopefuls look to comparative effectiveness analysis to address price and access issues
|
|
|
|
|
|
|
|
|
Relaunching Reform
|
|
|
| By
Humphrey Taylor
|
|
|
|
This time, powerful interest groups (like pharma) that sank the Clinton healthcare bill are on the side of change
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Buddy System
|
|
|
| By
Jean-Marc Niemetz
|
|
|
|
Jean-Marc Niemetz on forming partnerships with the industry's major stakeholders
|
|
|
|
|
|
|
|
|
Perfectly Imperfect
|
|
|
| By
Sander Flaum
|
|
|
|
Everyone makes mistakes; how you handle them is the measure of a true leader
|
|
|
|
|
|
|
|
|
Everybody's Right
|
|
|
| By
Patrick Clinton
|
|
|
|
The great debate on DTC advertising is heating up again. We're going to be hearing a lot about fair balance and risk communication and costs. But what about the patients?
|
|
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
